- Home
- SXTP vs DRMA Comparison
SXTP vs DRMA Comparison
Compare SXTP & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- DRMA
- Stock Information
- Founded
- SXTP 2010
- DRMA 2014
- Country
- SXTP United States
- DRMA United States
- Employees
- SXTP N/A
- DRMA N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- DRMA Health Care
- Exchange
- SXTP Nasdaq
- DRMA Nasdaq
- Market Cap
- SXTP 2.7M
- DRMA 2.2M
- IPO Year
- SXTP 2023
- DRMA 2021
- Fundamental
- Price
- SXTP $0.83
- DRMA $1.33
- Analyst Decision
- SXTP Hold
- DRMA Strong Buy
- Analyst Count
- SXTP 1
- DRMA 1
- Target Price
- SXTP N/A
- DRMA $6.00
- AVG Volume (30 Days)
- SXTP 967.9K
- DRMA 230.6K
- Earning Date
- SXTP 11-14-2024
- DRMA 11-13-2024
- Dividend Yield
- SXTP N/A
- DRMA N/A
- EPS Growth
- SXTP N/A
- DRMA N/A
- EPS
- SXTP N/A
- DRMA N/A
- Revenue
- SXTP $462,612.00
- DRMA N/A
- Revenue This Year
- SXTP $141.35
- DRMA N/A
- Revenue Next Year
- SXTP $175.16
- DRMA N/A
- P/E Ratio
- SXTP N/A
- DRMA N/A
- Revenue Growth
- SXTP 128.99
- DRMA N/A
- 52 Week Low
- SXTP $0.70
- DRMA $1.00
- 52 Week High
- SXTP $10.67
- DRMA $8.66
- Technical
- Relative Strength Index (RSI)
- SXTP 36.41
- DRMA 51.81
- Support Level
- SXTP $0.87
- DRMA $1.30
- Resistance Level
- SXTP $0.95
- DRMA $1.48
- Average True Range (ATR)
- SXTP 0.14
- DRMA 0.12
- MACD
- SXTP -0.06
- DRMA 0.00
- Stochastic Oscillator
- SXTP 6.99
- DRMA 49.66
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.